Earnings summaries and quarterly performance for Aktis Oncology.
Research analysts who have asked questions during Aktis Oncology earnings calls.
Recent press releases and 8-K filings for AKTS.
Aktis Oncology, Inc. implements new corporate governance and capital structure with IPO
AKTS
Board Change
- Aktis Oncology, Inc. filed an Amended and Restated Certificate of Incorporation and Bylaws on January 12, 2026, in connection with the completion of its initial public offering (IPO).
- The company's capital structure now includes authorized 480,000,000 shares of Common Stock, 10,000,000 shares of Class A Common Stock, and 10,000,000 shares of undesignated Preferred Stock.
- Key governance changes include the establishment of a classified Board, requiring two-thirds approval to remove a director for cause, and the elimination of stockholders' ability to take action by written consent.
- Holders of Class A Common Stock have the right to convert each share into one share of Common Stock at a 1:1 ratio, subject to a beneficial ownership limitation.
- The Delaware Court of Chancery is designated as the sole and exclusive forum for certain corporate actions, and federal district courts for causes of action under the Securities Act or Exchange Act.
Jan 12, 2026, 9:03 PM
Quarterly earnings call transcripts for Aktis Oncology.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more